Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.39
+0.13002.47%
Pre-market: 5.390.00000.00%08:18 EDT
Volume:1.96M
Turnover:10.46M
Market Cap:1.10B
PE:-9.32
High:5.44
Open:5.25
Low:5.21
Close:5.26
52wk High:7.01
52wk Low:3.21
Shares:204.66M
Float Shares:198.20M
Volume Ratio:1.32
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5782
EPS(LYR):-0.5344
ROE:-105.48%
ROA:-50.15%
PB:7.68
PE(LYR):-10.09

Loading ...

Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)

TIPRANKS
·
Aug 26

Savara announces presentations of Results from Phase 3 trial of Molgramostim

TIPRANKS
·
Aug 25

Savara to Present Phase 3 Impala-2 Molgramostim Data in Autoimmune Pulmonary Alveolar Proteinosis at ERS 2026

Reuters
·
Aug 25

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2026

THOMSON REUTERS
·
Aug 25

Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares

Reuters
·
Aug 21

Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi

Reuters
·
Aug 12

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Benzinga Earnings
·
Aug 12

Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Savara Q2 Loss Widens as Operating Expenses Rise

Reuters
·
Aug 12

Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta

Reuters
·
Aug 12

Savara Q2 Net Income USD -40.228 Million

Reuters
·
Aug 12

Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041

THOMSON REUTERS
·
Aug 12

Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively

THOMSON REUTERS
·
Aug 12

Savara announces EPO granted a patent covering formulation of Molbreevi

TIPRANKS
·
Jul 30

Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041

Reuters
·
Jul 30

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of Molbreevi*, Providing Protection in Europe and Australia Until March 2041

THOMSON REUTERS
·
Jul 30

Savara Posts Corporate Presentation Focused on Autoimmune Pulmonary Alveolar Proteinosis and Molbreevi Program

Reuters
·
Jul 16

Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors

Reuters
·
Jun 30

Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?

Simply Wall St.
·
Jun 30

Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?

Simply Wall St.
·
Jun 28